Literature DB >> 28969116

Natural Killer Cells - Their Role in Tumour Immunosurveillance.

Preeti Sharma1, Pradeep Kumar2, Rachna Sharma3.   

Abstract

An important component of the innate immune system, the natural killer cells that originate from the lymphoid cell lineage, hold tremendous potential as an effective therapeutic tool to combat a variety of cancers. Their vast capability to kill altered cells such as opsonized cells (antibody coated), tumour cells, genotoxically changed cells without affecting the healthy cells of the body, make them an effective therapeutic agent for various types of cancers. Besides, through interplay and molecular crosstalk via several cytokines, they also augment the adaptive immune response by, promoting the differentiation, activation and recruitment of component cells of the system. With the current advance knowledge of Natural Killer (NK) cells, their receptor-ligand interactions involved in functional regulation, various mechanistic approaches involving the role of cytokines led to desired modulation of NK cell activity in a tailor-made manner, for triggering clinically relevant responces. Several strategies have been adopted by researchers, to augment the efficacy of NK cells. Still many challenges exist for increasing the therapeutic relevance of these cells.

Entities:  

Keywords:  Antibody dependent cellular toxicity; Immunotherapy; Mechanism; Natural killer cell receptors; Tumour surveillance

Year:  2017        PMID: 28969116      PMCID: PMC5620756          DOI: 10.7860/JCDR/2017/26748.10469

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  62 in total

Review 1.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

2.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

Review 3.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

4.  Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells.

Authors:  H J McKenna; P de Vries; K Brasel; S D Lyman; D E Williams
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

Review 5.  Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.

Authors:  Hiroshi Terunuma; Xuewen Deng; Zahidunnabi Dewan; Shigeyoshi Fujimoto; Naoki Yamamoto
Journal:  Int Rev Immunol       Date:  2008       Impact factor: 5.311

6.  Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.

Authors:  A Komiyama; H Kawai; A Yabuhara; M Yanagisawa; Y Miyagawa; M Ota; H Hasekura; T Akabane
Journal:  Pediatrics       Date:  1990-03       Impact factor: 7.124

7.  Role of IFN-alpha/beta and IL-12 in the activation of natural killer cells and interferon-gamma production during experimental infection with Trypanosoma cruzi.

Authors:  C Une; J Andersson; A Orn
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

8.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

9.  Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.

Authors:  Jason E Hudak; Stephen M Canham; Carolyn R Bertozzi
Journal:  Nat Chem Biol       Date:  2013-11-24       Impact factor: 15.040

10.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Authors:  U Koehl; C Kalberer; J Spanholtz; D A Lee; J S Miller; S Cooley; M Lowdell; L Uharek; H Klingemann; A Curti; W Leung; E Alici
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

View more
  10 in total

1.  FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.

Authors:  Young Min Chung; Wen Bin Tsai; Pragya P Khan; Jessica Ma; Jonathan S Berek; James W Larrick; Mickey C-T Hu
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 2.  Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer.

Authors:  Zachary R Stephen; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2020-11-25       Impact factor: 9.933

3.  CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.

Authors:  Haitao Wang; Shanji Nan; Ying Wang; Chengbi Xu
Journal:  J Cell Mol Med       Date:  2021-03-17       Impact factor: 5.310

4.  Minimum environmental enrichment is effective in activating antitumor immunity to transplanted tumor cells in mice.

Authors:  Daisaku Takai; Akiko Abe; Heita Miura; Satoshi Tanaka; Jun-Ichiro Komura
Journal:  Exp Anim       Date:  2019-07-11

Review 5.  Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells.

Authors:  Kate J Dixon; Jianming Wu; Bruce Walcheck
Journal:  Cancers (Basel)       Date:  2021-01-16       Impact factor: 6.639

6.  Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects.

Authors:  Dihia Meghnem; Sharon A Oldford; Ian D Haidl; Lisa Barrett; Jean S Marshall
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

7.  Reprogramming and redifferentiation of mucosal-associated invariant T cells reveal tumor inhibitory activity.

Authors:  Chie Sugimoto; Yukie Murakami; Eisuke Ishii; Hiroyoshi Fujita; Hiroshi Wakao
Journal:  Elife       Date:  2022-04-05       Impact factor: 8.713

8.  Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment.

Authors:  Lucy Golden-Mason; Rachel H McMahan; Michael S Kriss; Alexandra L Kilgore; Linling Cheng; Rachael J Dran; Amanda Wieland; Hugo R Rosen
Journal:  Hepatol Commun       Date:  2018-03-01

9.  Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice.

Authors:  Barbara Mertens; Tatiane Cristina de Araujo Nogueira; Dimitrios Topalis; Ruzena Stranska; Robert Snoeck; Graciela Andrei
Journal:  Oncotarget       Date:  2018-04-24

10.  The pandemic COVID-19: a tale of viremia, cellular oxidation and immune dysfunction.

Authors:  Adekunle Babajide Rowaiye; Olukemi Adejoke Onuh; Angus Nnamdi Oli; Okiemute Ajiroghene Okpalefe; Solomon Oni; Ezinne Janefrances Nwankwo
Journal:  Pan Afr Med J       Date:  2020-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.